Pain drug developer Horizon Pharma takes a shot at $49.5M IPO, below expected range
This article was originally published in Scrip
Executive Summary
Horizon Pharma has filed for an initial public offering on Nasdaq of up to $49.5 million through the sale of 5.5 million shares at $9 per share, which should provide the Northbrook, Illinois-based company some certainty as it prepares for the US launch next quarter of its recently approved product Duexis – a fixed-dose combination of ibuprofen and famotidine in a single pill. A decision from the EU on the product is expected in the first half of 2012.